Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study

Jamil, Zubia; Waheed, Yasir; Malik, Maryam; Durrani, Asghar Aurangzeb

doi:10.7717/peerj.4853

Cited by 7 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All the patients achieved undetectable HCV RNA at the end of treatment (ETR). This was similar to the results reported by Jamil et al where 98.7% of patients achieved ETR [12]. Comparable results were reported by researchers from other countries [14].…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Safety and Efficacy of Daclatasvir with Sofosbuvir and Ribavirin in Hepatitis C Virus Infection: A Real World Experience from South Punjab, Pakistan

Malghani

Chaudhary

Shahid

et al. 2021

Preprint

View full text Add to dashboard Cite

Background & Objectives: Sofosbuvir (SOF) and daclatasvir (DCV) in combination with ribavirin (RBV) drastically changed the treatment scenario of chronic hepatitis C (CHC) patients, achieving remarkable efficacy and safety profile. Real world experience of SOF/DCV/RBV combination in this part of Asia was scant. This study aimed to evaluate the efficacy and safety of SOF/DCV/RBV combination to treat CHC patients at a tertiary care hospital in South Punjab. Methods: Patients of CHC of any genotype were enrolled prospectively. They were treated with 12 weeks course of SOF/DCV/RBV combination. Effectiveness was evaluated by end of treatment response (ETR) and sustained virological response (SVR) at 12 and 24 weeks post-treatment. Adverse events were recorded for safety analysis. Results: We analyzed data of 102 patients of CHC (40 males and 62 females). The mean age was 40.04 + 10.22 years. Mean weight was 67.24 + 11.78 kg, while mean body mass index (BMI) was 26.32 + 4.58 kg/m2. Eighty patients belonged to low socio-economic status, while 22 belonged to middle socio-economic status. Sixty-four had a rural background, while 38 were from urban background. Seventy-four patients had no co-morbid condition; 16 (15.7%) had diabetes and 12 (11.8%) patients had co-morbid hypertension. Ninety percent of the patients did not have cirrhosis; 6% had compensated liver disease, while 4 % had decompensated liver disease. All the patients achieved undetectable HCV RNA at the end of treatment and 12 weeks after completion of treatment, while SVR at 24 weeks was achieved in 98% of patients. Only 2 patients discontinued treatment as a result of side effects. The most common side effects reported include fatigue, headache and fever. Conclusion: CHC is a grave problem in developing countries like Pakistan. The SOF/DCV/RBV combination is very effective in eradicating CHC and has a very good side effect profile as well.

show abstract

Section: Discussionsupporting

confidence: 92%

“…Almost 60 percent of the study population consisted of females. Our study was demographically comparable to other studies from Pakistan [11,12]. Most of the patients (78.4%) had a low socioeconomic status.…”

Section: Discussionsupporting

confidence: 87%

Safety and Efficacy of Daclatasvir with Sofosbuvir and Ribavirin in Hepatitis C Virus Infection: A Real World Experience from South Punjab, Pakistan

Malghani

Chaudhary

Shahid

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…None of the patients required blood transfusion. During treatment, none of the patients had significant hepatic decompensation or hyperbilirubinemia of >2.5mg/dl.In one patient (1.1%) platelet count dropped to 44,000 per mm 3 at the 12 th week of treatment, from a pretreatment value of 90,000 per mm 3 . However, patient did not experience any abnormal bleeding and platelet count subsequently improved to 70,000 per mm 3…”

Section: Safetymentioning

confidence: 86%

“…In 2017, in the global hepatitis report by World Health Organization, it was noted that in year 2015; globally 720,000 deaths were due to various complications of advanced chronic liver disease whereas 470,000 were related to hepatocellular carcinoma 1 . An estimated 11.55% of the adult Pakistani population is affected by hepatitis C, of which upto 91.8% have genotype 3a 3 . Another study from Pakistan, which showed a dismal average survival of only 23.9 months for patients presenting with hepatocellular carcinoma, revealed 84.4% had evidence of hepatitis C infection 4 .…”

Section: Introductionmentioning

confidence: 99%

Sofosbuvir-Velpatasvir Therapy in the Treatment of Chronic Hepatitis C Genotype 3

Khan

Mansoor

Fida

et al. 2021

PAFMJ

View full text Add to dashboard Cite

Objective: To determine the efficacy and safety of sofosbuvir-velpatasvir combination therapy in treatment ofchronic hepatitis C genotype 3. Study Design: Prospective cohort study. Place and Duration of Study: Department of Medicine, Combined Military Hospital Lahore, from Mar 2018 toOct 2019. Methodology: Eighty eight consecutive patients, who were ≥18 years of age with chronic hepatitis C as confirmed by polymerase chain reaction were included in the study. Primary end point was sustained virological response at 12 week post-treatment. Patients with any of the following criteria at presentation were excluded from study: aspartate/alanine aminotransferase >10 times the upper limit of normal, total bilirubin twice the upper limit of normal, haemoglobin <8g/dL, platelet count <30,000/uL, albumin <2 g/dL and creatinine clearance of <60 mL/ min. Additional criteria for exclusion included patients who had co-infection with hepatitis B or human immune deficiency virus (HIV), significant cardiac or lung disease, porphyria, liver cirrhosis caused by non-HCV related causes or co-existent hepatocellular carcinoma. Results: Overall sustained virological response was achieved in 82 of 84 patients (97.6%). One of the patients with genotype 3 had detectable HCV RNA at end of treatment, which became undetectable at 12 weeks, post-treatment. 38 /38 (100%) patients without cirrhosis while 41/43 patients (95.3%) with compensated cirrhosis and 3/3 with decompensated cirrhosis achieved sustained virological response. Two (2.3%) patients had on-treatment virological failure. Four patients were lost to follow up. Conclusion: Treatment with sofosbuvir and velpatasvir is effective and well tolerated in patients with chronichepatitis C, genotype 3.

show abstract

“…Although there is no vaccine available against HCV, very effective drugs are available for the treatment of HCV. 6 After the clearance of HCV infection, the immune system of the person may not be able to clear a subsequent infection completely. Having a household contact with an HCV positive patient is also a risk factor.…”

Section: Introductionmentioning

confidence: 99%

Familial clustering of hepatitis C virus in a Pakistani population

Jamil

Waheed

Ahsan

et al. 2020

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Pakistan has the second‐highest burden of hepatitis C patients in the world. A total of 683 individuals, who visited the Liver Clinic during the study period, were screened for the presence of hepatitis C virus (HCV) infection. A total of 534 individuals who showed positive HCV infection were grouped into the case group and 149 individuals with HCV negative status were grouped into the control group. A detailed questionnaire was used to collect demographic, clinical, HCV risk factor, and familial clustering data. HCV familial clustering was found in 30.1% in the case group compared with 17.4% in the control group. We also found 17% of patients had spouses who were also infected with HCV compared to 4% spouse infection in the control group. Only 3.7% of patients had HCV positive mothers. These results were further expanded by regression analysis that showed that family history and sexual history are independent risk factors for transmission of hepatitis C infection and mother's history has no significance as a risk factor for transmission. The major risk factor for getting HCV infection are dental procedures, unsafe injections, surgery, and blood transfusions. There is a strong need to increase awareness about HCV transmission routes among positive patients to reduce the chances of HCV familial clustering.

show abstract

Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study

Cited by 7 publications

References 21 publications

Safety and Efficacy of Daclatasvir with Sofosbuvir and Ribavirin in Hepatitis C Virus Infection: A Real World Experience from South Punjab, Pakistan

Safety and Efficacy of Daclatasvir with Sofosbuvir and Ribavirin in Hepatitis C Virus Infection: A Real World Experience from South Punjab, Pakistan

Sofosbuvir-Velpatasvir Therapy in the Treatment of Chronic Hepatitis C Genotype 3

Familial clustering of hepatitis C virus in a Pakistani population

Contact Info

Product

Resources

About